Congresses
Tumor Area and Microscopic Extent of Invasion to Estimate Circulating Tumor DNA Fraction in Plasma and Detectability of Colorectal Cancer
January 24, 2020
Performance of a Blood-based Test for the Detection of Multiple Cancer Types
January 23, 2020
Oral Presentation: Performance of A Blood-based Test for the Detection of Multiple Cancer Types
Blood-based cancer detection in plasma cell-free DNA (cfDNA): evaluating clinical and pathologic tumor characteristics in participants with breast cancer
December 13, 2019
Oral Presentation: Novel non-invasive cell-free nucleic acid-based diagnostic test for liver fibrosis in patients with type II diabetes
November 10, 2019
Optimized Early Cancer Detection from Whole-Genome Sequencing of Cell-Free DNA
October 16, 2019
Oral Presentation: Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cellfree DNA (cfDNA)
October 11, 2019
Simultaneous Multi-cancer Detection and Tissue of Origin (TOO) Localization Using Targeted Bisulfite Sequencing of Plasma Cell-free DNA (cfDNA)
Oral Presentation: Multi-cancer detection of early-stage cancers with simultaneous tissue localization using a plasma cfDNA-based targeted methylation assay
September 27, 2019
Trial in Progress: Cancer Screening Study With or Without Low Dose Lung CT to Validate a Multi-cancer Early Detection Blood Test: SUMMIT
September 8, 2019
Prognostic Significance of Blood-based Cancer Detection in Plasma Cell-free DNA (cfDNA): Evaluating Risk of Overdiagnosis
June 3, 2019
The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on Non-cancer Participants with Cancer-like Cell-free DNA Signals
June 1, 2019
The Circulating Cell-free Genome Atlas (CCGA) Study: Size Selection of Cell-free DNA (cfDNA) Fragments
Genome-wide Cell-free DNA (cfDNA) Methylation Signatures and Effect on Tissue of Origin (TOO) Performance
MODELING REDUCTIONS IN ABSOLUTE CANCER MORTALITY FROM DIAGNOSING CANCERS BEFORE METASTASIS, 2006-2015
May 22, 2019
Tumor Shedding into Cell-free DNA (cfDNA) is Associated with High-mortality Cancers
May 10, 2019
Detection of Tissue-specific RNA in the Plasma of Cancer Patients: A Circulating Cell-free Genome Atlas (CCGA) Substudy
May 9, 2019
Cell-free DNA (cfDNA) Fragment Length Patterns of Tumor- and Blood-derived Variants in Participants With and Without Cancer
April 2, 2019
Plasma-Based Molecular Testing for Early Detection of Lung Cancer
November 8, 2018
Plasma Cell-free DNA (cfDNA) Assays for Early Multi-cancer Detection: the Circulating Cell-free Genome Atlas (CCGA) Study
October 19, 2018
Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: exploratory analysis of the Circulating Cell-free Genome Atlas (CCGA) study
June 5, 2018
Genome-Wide Sequencing for Early Stage Lung Cancer Detection from Plasma Cell-Free DNA (cfDNA): The Circulating Cell-free Genome Atlas (CCGA) Study
June 4, 2018
Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study
Breast Cancer Cell- free DNA (cfDNA) Profiles Reflect Underlying Tumor Biology: The Circulating Cell-free Genome Atlas (CCGA) Study
June 2, 2018
Development of Plasma Cell-Free DNA Assays for Early Cancer Detection: First Insights from the Circulating Cell- Free Genome Atlas (CCGA) Study
April 17, 2018
Development of Cell-Free Nucleic Acid-Based Tests for Detection of invasive breast cancer: The STRIVE Study
December 8, 2017
Conta: Methods for detecting trace amounts of contamination
July 24, 2017
Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer
June 3, 2017